- A
n
-1-
•
•

UTILITY	PATENT APPLICATION	TRANSMITTAL
, ,	(Small Entity)	

2290.00101

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission 98

Docket No.

TO THE ASSISTANT COMMISSIONER FOR PATENTS

	PTO				-			Patent Applica hington, D.C. 20	tion	IONTATEMIO		
Trans	mitte	ed he	rewith fo	r fil	ling under (35 U.S	S.C. 111((a) and 37 C.F.R.	1.53	B(b) is a new utility patent ap	plication for an	
			STER									PTO
												S.
and ir	wont	od b										D F
				ior:	a Ron, Elis	ha Or	r and Yo	ssi Paitan				3¢87
										the requisite information:		
Whic			tion []	Divisional		Contin	uation-in-part (IP)	of prior application No.:	09/240,537	
			tion 🗆	1	Divisional		Contin	uation-in-part ((:IP)	of prior application No.:		
Whiel						_		audon in pure (··· ,	or prior application No		
	Cont	inua	tion 🗆) ;	Divisional		Contin	uation-in-part (0	IP)	of prior application No.:		
Enclo	sed a	are:										
S and a second							App	olication Elemen	ts			
1 1 2	X	Filir	ng fee as	ca	lculated ar	ıd trar	nsmitted	as described belo	w			
2	×	Spe	ecification	ı ha	aving		32	pages a	nd ir	ncluding the following:		
r denier.	_							pages		rollaging the lone wing.		
	a.				e Title of th							
	b.							cations (if applica	•			
									ı/De	velopment (if applicable)		
	d.							(if applicable)				
		XI			nd of the In							
	f.	X			mary of the						•	
	g.	X				ie Dra	wings <i>(if</i>	f drawings filed)				
		X			escription							
	i.	X			s Classified		w					
	j.	X	Abstrac	t of	the Disclo	sure						-

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 2290.00101

Total Pages in this Submission 98

Application Elements (Continued)

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)				
	a.	☐ Formal b. ☑ Informal Number of Sheets1				
4.	X	Oath or Declaration				
	a.	□ Newly executed (original or copy) □ Unexecuted				
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)				
	C.	☑ With Power of Attorney ☐ Without Power of Attorney				
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).				
	×	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.				
6.		Computer Program in Microfiche				
7.	X	Genetic Sequence Submission (if applicable, all must be included)				
	a.	☑ Paper Copy				
	b.	☐ Computer Readable Copy				
	C.	Statement Verifying Identical Paper and Computer Readable Copy				
- chap-2		Accompanying Application Parts				
8.		Assignment Papers (cover sheet & documents)				
9.		37 CFR 3.73(b) Statement (when there is an assignee)				
10.		English Translation Document (if applicable)				
11.	×	Information Disclosure Statement/PTO-1449 Copies of IDS Citations				
12.	×	Preliminary Amendment				
13.	×	Acknowledgment postcard				
14.	×	Certificate of Mailing				
		☐ First Class ☒ Express Mail (Specify Label No.): EL405596413US				

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 2290.00101

Total Pages in this Submission 98

		Accompanying Application Parts (Continued)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	×	Small Entity Statement(s) - Specify Number of Statements Submitted:1
17.		Additional Enclosures (please identify below):
18.		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2) Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under
		a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **2290.00101**

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee Total Claims 16 -20 =0 \$9.00 \$0.00 х Indep. Claims 8 - 3 = 5 \$200.00 \$40.00 Multiple Dependent Claims (check if applicable) \$0.00 **BASIC FEE** \$355.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$555.00 A check in the amount of \$555.00 to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below. A duplicate copy of this sheet is enclosed. ☐ Charge the amount of as filing fee. Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Dated: November 10, 2000

CC:

Signature

Amy E. Rinaldo, Reg. No. 45,791

30500 Northwestern Highway, Suite 410 Farmington Hills, Michigan 48334

KOHN & ASSOCIATES

(248) 539-5050

Attorney's Docket Number: 2290.00074

Applicant or Patentee:	Rosenberg et al.				
Serial or Patent No:					
Filed or Issued:	Herewith				
For:	GENE CLUSTER				
VERIFIED STATES	MENT (DECLARATION) CLAIMING SMALL ENTITY STATUS				
	.9(f) and 1.27(d) SMALL BUSINESS CONCERN				
I hereby declare that I a	m:				
the owner of	f the small business concern identified below:				
X an official act on behalf	of the small business concern empowered to lf of the concern identified below:				
Name of Concern:	RAMOT-UNIVERSITY AUTHORITY FOR APPLIED RESEARCH				
	AND INDUSTRIAL DEVELOPMENT, LTD.				
Address of Concern:	32 Haim Levanon Street - P.O. Box 39296				
	Tel-Aviv 61392 Israel				
small business concern as 1.9(d), for purposes of p 35, United States Code, i those of its affiliates, statement: (1) the numbe over the previous fiscal time, part-time or temporaryear, and (2) concerns indirectly, one concern third-party or parties could be be seen as a concern the concern th	above identified small business concern qualifies as a selection of the concern and the concern and the concern and the concern are described by the concern and the concern are described by				
invention referenced above	pusiness concern identified above with regard to the				
Described in:					
	ation filed herewith.				
	referenced above.				
patent refer	renced above.				

The same of the sa

If the rights held by the above-identified small by ness concern are not exclusive, each is idual, concern or organization wing rights to the "invention is listed below" and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c), if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

* NOTE: Separate verified statements are required from each

named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27) NAME: ADDRESS: Individual ___ Small Business ___ Nonprofit Organization NAME: ADDRESS: Individual ___ Small Business ___ Nonprofit Organization I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)] I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed. Date: 2 June 1998 SIGNATURE: Hananel Kvatinsky Manager-Patents Department 2 June 1998 Date: SIGNATURE: Rami Finkler President/General Manager Address of Persons Signing: 32 Haim Levanon Street Tel Aviv 61392 ISRAEL 37994 TRAMUT

(Small Entity-Small Business (Form 7-4) -- Page 2 of 2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Eugene Rosenberg, et al.

Continuation of United States Patent

Application No. 09/240,537, filed: 01/29/99

Filed:

Herewith

For:

GENE CLUSTER

Attorney Docket No. 2290.00101

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231
Box Patent Application

Dear Sir:

Please preliminarily amend the above-captioned Continuation patent application prior to examination as follows:

IN THE SPECIFICATION:

Page 1, in the "Cross-Reference to Related Application Section", after "This is a", please insert:

--Continuation application of United States Patent Application Serial No.: 09/240,537, filed January 29, 1999, all of which is incorporated herein by reference---.

Page 3, line 17, please delete "1 and".

Page 4, line 12, after "DNA", please insert -- and amino acid--.

IN THE CLAIMS:

- 1. (Twice Amended). A purified, isolated and cloned DNA or amino acid sequence encoding a polypeptide required for the synthesis of antibiotic TA [or a shorter polypeptide portion of said polypeptide] , said polypeptide being selected from the group consisting essentially of SEQ ID NOS 1-19 and analogs thereof.
- 3. (Twice Amended). A purified, isolated and cloned DNA or amino acid sequence consisting of a [DNA] sequence encoding a polypeptide required for post modification of antibiotic TA [or a shorter polypeptide portion of said polypeptide] said polypeptide being selected from the group consisting essentially of SEQ ID NOS 1-19 and analogs thereof.
- 5. (Amended) A purified, isolated and cloned DNA or amino acid sequence consisting of a [DNA] sequence encoding a gene product involved in a regulation of the biosynthesis of antibiotic TA said polypeptide being selected from the group consisting essentially of SEQ ID NOS 1-19 and analogs thereof.
- 7. (Twice Amended) A purified, isolated and cloned DNA sequence consisting of a DNA sequence as set forth in SEQ ID NO: [1 and] 2.

8. (Twice Amended) The DNA sequence of SEQ ID NO: [1 and] 2 altered by point mutations, deletions or insertions such that the resulting amino acid sequence is shortened.

Claim 9, line 1, please delete "1 or".

- 15. (Twice Amended) A method of combinatorial genetics using the TA genes as set forth in SEQ ID NOS 1-19 for use in combinatorial genetics.
- 16. (Twice Amended) <u>A method of encoding for the synthesis,</u> modification or regulation of antibiotic TA by using a TA gene as set forth in SEQ ID NOS 1-19 for encoding for the synthesis, modification or regulation of antibiotic TA.

REMARKS

Claims 1-16 are currently pending in the application. Claims 1, 3, 5, 7, 8, 9, 11 and 16 are in independent form.

The Office Action states that the Information Disclosure Statement filed on February 15, 2000 fails to comply with 37 CFR 1.198(a)(2), which requires a legible copy of each U.S. and foreign patent and each publication which is listed. Copies of the missing references are attached hereto.

Claims 1-6 stand rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the invention was filed, had possession of the claimed invention.

The Office Action states that the instant claims are directed to DNA sequences encoding or partially encoding polypeptides for the synthesis, post-modification, and/or regulation of the antibiotic TA where the claimed products are defined by their functional characteristics. However, the Office Action holds that in claims to genetic material a generic statement such as "vertebrate insulin cDNA" without more is not an adequate written description of the genus since it does not distinguish the genus from others, except by function. The Office Action concludes that one skilled in the art cannot visualize or recognize the identity of the members of the genus. However, the claims as pending do state that there must be present a specific polypeptide which is utilized in the synthesis of antibiotic TA. This statement does sufficiently describe a structural feature commonly possessed by members of the genus such that the members of the genus must include therein at least one polypeptide which is utilized in the synthesis, post-modification or regulation of the antibiotic TA. Accordingly, reconsideration of the rejection is respectfully requested.

Claims 7-9 and 10-14, stand rejected under 35 U.S.C. Section 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. Specifically, the Office Action states that in the claims the sequence numbers are referred to as DNA sequences, while in the Sequence Listing they are referred to as amino acid sequences. This was an error found in the Sequence Listing, which error has been remedied with the attached Sequence Listing. This correction thus obviates the present rejection.

The Office Action states that claims 15 and 16 are rejected under 35 U.S.C. Section 101 because the claimed recitation of a use, without setting forth any further steps involved in the process, results in an improper definition of a process. Accordingly, both claims 15 and 16 have been amended to either recite a proper method claim or the language has been amended to no longer recite a method claim. Reconsideration of the rejection is respectfully requested.

Claims 1-2 stand rejected under 35 U.S.C. Section 102(b) as being anticipated by general scientific knowledge. The Office Action states that in claim 1, line 1, the claim to "DNA sequences partially encoding...polypeptides" without defining the term "partially" claims fragments as small as three nucleotides, or a single code, encoding one amino acid would be included in the claim. Furthermore, the Office Action states that the nucleotide database of GenBank

contains greater than 100 nucleotide sequences from the cited species at the time the invention was made, all of which anticipate claims 1-2. However, when read more specifically, none of the published sequences were required for the biosynthesis or post-modification of antibiotic TA. Additionally, there were no cited references teaching the claimed sequences. As a matter of law, there must be a reference cited which teaches subject matter even if the subject matter is held to be in the general knowledge. That is, any holding of a limitation being in the general knowledge must be supported by a citation. Since the prior art does not disclose any sequences for the biosynthesis or post-modification of antibiotic TA as recited in pending claims 1 and 2, the claims are not anticipated by the cited general scientific knowledge and reconsideration of the rejection is respectfully requested.

Claim 8 stands rejected under 35 U.S.C. Section 102(b), as being anticipated by general scientific knowledge. The Office Action cites that in claim 8, line 2, the claim recites DNA sequences resulting in truncated amino acid sequences. The Office Action states that without any further limitation of the term "truncated", this claim language broadly encompasses DNA fragments as small as three nucleotides, or a single code on which sequences are found throughout scientific literature. Claim 8 has been amended in order to further prosecution, to remove the term "truncated". Additionally, when read more specifically, none of the published sequences were required for the biosynthesis or post-modification

of antibiotic TA. As this requirement is recited in the claim language of pending claims 1 and 2, these claims are not anticipated by the cited general scientific knowledge. Reconsideration of the rejection is respectfully requested.

It is respectfully requested that the present amendment be entered in order to place the application in condition for allowance or at least in better condition for appeal. The application is placed in condition for allowance as it addresses and resolves each and every issue that remains pending. The amendments overcoming the rejections under 35 USC 112 are made exactly as suggested by the Office Action. Claims have also been amended to clearly distinguish over the prior art. The application is made at least in better condition for appeal as the amendment removes many issues thereby simplifying the issues on appeal. That is, each and every rejection under 35 USC 112 has been overcome exactly as suggest in the Office Action. Further, the claims have been amended to more specifically define the invention while raising no new issues which would require any further searching. Rather, the amendments have been made in view of comments made in the Office Action which clearly distinguish the presently pending claims over the cited prior art. Hence, it is respectfully requested that the amendment be entered.

In conclusion, it is respectfully requested that the present amendment be entered in order to place the application in condition for allowance, which allowance is respectfully requested.

The Commissioner is authorized to charge any fee or credit any overpayment in connection with this communication to our Deposit Account No. 11-1449.

Respectfully submitted,

KOHN & ASSOCIATES

Amy E. Rinaldo Registration No. 45,791 30500 Northwestern Hwy. Ste. 410 Farmington Hills, Michigan 48334 (248) 539-5050

Dated: November 10, 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on Newember 10, 2000.

Connie Herty

GENE CLUSTER

BACKGROUND OF THE INVENTION

5

10

15

Polyketides constitute a large and highly diverse group of secondary metabolites synthesized by bacteria, fungi and plants, with a broad range of biological activities and medical applications. They include anti-cancer agents (Daunorubicin), antibiotics (tetracyclines, erythromycin etc.), immunosuppressants (macrolide FK506) and compounds with mycotoxic activity (aflatoxins, ochratoxins, ergochromes, patulin etc.). Polyketides are synthesized by repetitive condensations of acetate or propionate monomers in a similar way to that of fatty acid biosynthesis. Structural diversity of polyketides is achieved through different thioester primers, varying chain extension units used by the polyketide synthases (PKSs), and variations in the stereochemistry and the degree of reduction of intermediates. Diversity is also achieved by subsequent processing, such as alkylations, oxidations, O-methylations, glycosylations and cyclizations. Genetic studies indicated that gene organization of functional units and motif patterns of various PKSs are similar. This similarity was used to identify and obtain new PKS systems in both gram negative and gram positive bacteria.

20

PKS systems are classified into two types: type I PKSs are large, multifunctional enzymes, containing a separate site for each condensation or modification step. These represent "modular PKSs" in which the functional domains

And the first the first the first three the first three three the first three three

encoded by the DNA sequence are usually ordered parallel to the sequence of reactions carried out on the growing polyketide chain. Type II PKSs are systems made up of individual enzymes, in which each catalytic site is used repeatedly during the biosynthetic process.

5

Genetic studies on prokaryotic PKSs have focused on gram positive microorganisms, particularly on actinomycetes. Myxobacteria are gram negative bacteria that produce a large number of secondary metabolites, including polyketides. Myxococcus xanthus produces TA (Rosenberg, et al., 1973; Rosenberg, et al., 1984), which is an antibacterial antibiotic.

10

The polyketide antibiotic Tel-Aviv (hereinafter TA) (Rosenberg, et al., 1973) is synthesized by the gram negative bacterium *Myxococcus xanthus* in a unique multistep process incorporating a glycine molecule into the polyketide carbon chain, which is elongated through the condensation of 11 acetate molecules by a type I polyketide synthase (PKSs).

20

15

The antibiotic TA was crystallized and its chemical properties were determined. It is a macrocyclic polyketide synthesized through the incorporation of acetate, methionine, and glycine. It inhibits cell wall synthesis by interfering with the polymerization of the lipid-disaccharide-pentapeptide and its ability to adhere avidly to tissues and inorganic surfaces makes it potentially useful in a wide range of clinical applications, such as treating gingivitis.

A growing interest in the study of PKS systems and peptide synthetase systems stems from the need to develop new potent biologically active compounds. The use of combinatorial genetics in both systems (PKS and peptide synthetase) separately has led to the production of new polyketides and new peptides.

5

It would therefore by useful to be able to generate new biological agents from secondary metabolites of the antibiotic TA.

SUMMARY OF THE INVENTION

10

According to the present invention, there is provided a purified, isolated and cloned DNA sequence partially encoding a functional portion of a polypeptide component required for the synthesis of antibiotic TA. Also provided are purified, isolated and cloned DNA sequences encoding a polypeptide component required for postmodification of antibiotic TA and encoding a gene product involved in the regulation of the biosynthesis of antibiotic TA. A purified, isolated and cloned DNA sequence having a DNA sequence (Seq. ID No:1 and 2) encoding a polypeptide component required for encoding the TA gene cluster and any mutations thereof is provided. Also provided are methods of using the TA genes for combinatorial genetics and of using the TA genes encoding for synthesis and modification or regulation of antibiotic TA.

20

15

5

10

15

20

DESCRIPTION OF THE DRAWING

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawing wherein:

Figure 1 shows the physical maps of the DNA regions involved in TA synthesis.

DETAILED DESCRIPTION OF THE INVENTION

The present invention consists of a DNA sequence of at least 42 kb encoding genes involved in TA production and *Myxococcus xanthus* as best shown in Seq. ID No:1 through 17 and cosmid clones containing the entire TA gene DNA sequences. The TA gene cluster has been purified, isolated, and cloned. The purification, isolation and cloning was done according to the methods described in Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.

A DNA fragment of at least 42 kb (Figure 1), encoding genes involved in TA production in *Myxococcus xanthus* has been identified, cloned and analyzed. These steps were done in accordance with Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996. This

5

10

15

20

fragment contains a large region of about 20 kb, encoding the genes responsible for the regulation and the post-modification of TA. An additional fragment of approximately 8-10 kb located 10-20 kb downstream of the post-modification region, encodes the enzyme responsible for the incorporation of the glycine into the polyketide chain. This novel polypeptide is made up of a peptide synthetase unit lying between two PKS modules.

The potential of this unique polypeptide in combining the two systems can lead to a new family of compounds, emerging from various combinations which can be utilized for combinatorial genetics. Such utilization can produce, for example, new bioactive agents, new polyketides and new peptides. Additionally, the TA gene cluster can be utilized in a method for the synthesis, modification or regulation of the TA antibiotic.

Mutations imparting defects into the TA gene cluster can be point mutations, deletions or insertions. The mutations can occur within the nucleotide sequence of the allele of the TA gene cluster such that the resulting amino acid sequence of the TA gene cluster product is altered.

In one embodiment of the present invention, the TA gene cluster can be included in a vector or recombinant expression vector. This vector containing the TA gene cluster is able to transform a suitable eucaryotic or procaryotic host cell. A suitable host cell can be determined by one skilled in the art. An example of a

suitable cell which can be transformed by the TA gene cluster is an E. coli cell.

In another embodiment of the present invention, the a DNA fragment encoding the TA gene cluster can be cloned into a cosmid, as shown in Figure 1. This DNA fragment contains a large region of about 20kb, encoding the genes responsible for the regulation and the post-modification of TA. An additional fragment of approximately eight to ten kb is located 10-20 kb downstream of the post-modification region and encodes the enzyme responsible for the incorporation of the glycine into the polyketide chain. The novel polyketide chain is made up of a peptide synthetase unit lying between two PKS modules (See Figure 1).

The above discussion provides a factual basis for the use of the TA gene cluster. The methods used with and the utility of the present invention can be shown by the following non-limiting examples and accompanying figure.

15

20

10

5

EXAMPLES

GENERAL METHODS:

METHODS:

General methods in molecular biology: Standard molecular biology techniques known in the art and not specifically described are generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989). Polymerase

chain reaction (PCR) is carried out generally as in *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990). Reactions and manipulations involving other nucleic acid techniques, unless stated otherwise, are performed as generally described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference. In-situ (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822.)

10

20

5

Recombinant Protein Purification

Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.

15 Example 1:

Analysis of the TA gene cluster by chromosomal restriction map.

Chromosomal DNA of several transposition mutants (ER-2514, ER-1037, ER-1030, ER-1311, ER-7513, ER-3708, ER-4639 and ER-6199; Varon *et al.*, 1992) was extracted, digested with restriction enzymes that cut within the transposon, and analyzed by Southern hybridization with six different probes (originating from TnV and Tn5lac). We used probes designed to hybridize either to the entire transposon, or to its 5' or 3' ends. A chromosomal restriction map of the whole gene cluster was constructed on the basis of these results (Figure 1). The data refined the transduction

map (Varon et al., 1992) and further indicated that all the genes in the cluster are transcribed in the same direction (see Figure 1).

Preparation of TA-specific probes

DNA from the TnV mutant ER-4639, ER1311 and ER-6199 was digested with KpnI (does not restrict TnV), self-ligated and transformed into E. coli XL1-Blue MR using the transposon-derived kanamycin resistance for selection. Tranformant clones pPYT4639, pPYT1311/p5 and pPYT6199 carried a 1.5 kb, 2.3 kb and a 11.2 kb fragment, respectively (see Figure 1).

10

5

Cloning of a M. xanthus DNA region encoding genes involved in TA biosynthesis.

15

A library of *M. xanthus* ER-15 was constructed in the cosmid vector SUPERCOS-1 and screened using specific TA probes obtained from transposition mutants (ER-4639, ER-1311 and ER-6199, see map) that contain a TnV transposon. Seventy four recombinant cosmids that carried genes required for TA production were identified through colony hybridization. The cosmids, pPYCC64 and pPYCC44, which hybridized to these probes were further characterized through restriction analysis (see Figure 1) and sub cloned for sequencing.

20

Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in

5

10

their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

REFERENCES

- 1. Rosenberg, E., Vaks, B. and Zuckerberg. A. Bactericidal action of an antibiotic produced by Myxococcus xanthus. Antimicrob. Agents. Chemother. 4:507-513 (1973).
- 2. Rosenberg, E., Porter, J.M., Nathan, P.N., Manor, A. and Varon, M. Antibiotic TA: an adherent antibiotic. Bio/Technology. 2:796-799 (1984).
 - 3. Varon et al., 1992
- 4. Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.
 - 5. Testoni et al, 1996, Blood 87:3822.
- 6. PCR Protocols: A Guide To Methods And Applications, Academic Press, San Diego, CA (1990).
- 7. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992).
- 8. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989).

SEQ LISTING PAGE(s)

REGION 1:

Tal - Peptidesynthetase unit-PKS module.

FRAGMENT size(aa):2392

VDPARLTRAWEGLLERYPLLAGAIRVEGTEPVIVPSGQVSAEVHEVPSVSDSALVATLRASAKVPFDLAC GPLARLHLYSRSEHEHVLLLCFHHLVLDGASVAPLLDALRERYAGTEAKAGLLEVPIVAPYRAAVEWEQ LAIGGDEGRRHLDYWRHVLATPVPPPLNLPTDRPRSATGLDSEGATHSQRVPTEQALRLREFARAQQVS LPTVLLGLYYALLHRHTRQDDVVVGIPTMGRPRAELATAIGYFVNVMAVRARGLGQHSFGSLLRHLHDS VIDGLEHAHYPFPRVVKDLRLSNGPEEAPGFQTMFTFQSLQLTSAPPRPEPRSGGLPELEPLDCVHQEGAY PLELEVVEGAKGLTLHFKYDARLYEADTVERMARQLLRAADQVADGVESPLSALSWLDDEERRTLLRD WNATATPFLEDLGVHELFQRQARETPDAMAVSYEGHSLSYQALDTRSREIAAHLKSFGVKPGALVGIYL DRSAELVAAMLGVLSAGAAYVPLDPVHPEDRLRYMLEDSGVVVVLARQASRDKVAAIAGASCKVCVLE DVKAGATSAPAGTSPNGLAYVIYTSGSTGRPKGVMIPHRGVVNFLLCMRRTLGLKRTDSLLAVTTYCFD IAALELLLPLCAGAQVIIASAETVRDAQALKRALRTHRPTLMQATPATWTLLFQSGWENAERVRILCGGE ALPESLKAHFVRTASDVWNMFGPTETTIWSTMAKVSASRPVTIGKPIDNTQVYVLDDRMQPVPIGVPGE LWIAGAGVACGYLNRPALTAERFVSNPFTPGTTLYRTGDLARWRADGEVEYLGRLDHQVKVRGFRIEM GEÏEAQLAGHPSVKNCAVVAKELNGTSQLVAYCQPAGTSFDEEAIRAHLRKFLPDYMVPAHVFAVDAIP LSGNGKVDRGQLMARPVVTRRKTSAVHARSPVEATLVELWKNVLQVNEVGVEDRFFEVGGDSVLAAV LVEEMNRRFDTRLAVTDLFKYVNIRDMARHMEGATAQARTGATEPAREDTASERDYEGSLAVIGISCQL PGAADPWRFWKNLREGRDSVVAYRHEELRELGVPEEVLRDSRYVAVRSSIEDKECFDPHFFGLTARDAS FMDPQFRLLLMHAWKAVEDAATTPERLGPCGVFMTASNSFYHQGSPQFPADGQPVLRTAEEYVLWVLA OAGSIPTMVSYKLGLKGPSLFVHTNCSSSLSALYVAQQALAAGDCQTALVGAATVFPSANLGYLHQRGL NFSSAGRVKAFDAAADGMIAGEGVAVLVVKDAAAAVRDGDPIYCLVRKVGINNDGQDKVGLYAPSAT GOAEVIRRLFDRTGIDPASIGYVEAHGTGTLLGDPVEVSALSEAFRTFTDRRGYCRLGSVKSNLGHLDTV AGLAGLIKTALSLRQGEVPPTLHVTQVNPKLELTDSPFVIADRLAPWPSLPGPRRAAVSAFGLGGTNTHAI LEHYPROSRPRERSQRSNAVRAVAPFSARTLEALKONLRALLOFLEOPASAEVALADITYTLQVGRVAMP ERMVVTASTRDELVEGLRRGIATVGGAHVGTVVDTSPSVDADARAVAEAWATGDSIDWDSLHGDVKP ARVSLPTYQFAKERYGLSPAHSVANSSKTHPDAGVPLFVPTWQPWSEGASNASLALRHLVVLCEPLDAL GAEGASALASTLADRRIEVVRTSSPSARLDARFMAHASAVFERVKALLSERLTAPVTLQVLVPEERDALA LSGLGSLLRSVSQENPLVRGQLIRVQGSVSASALVDYLVKSARAGDYTDSRYTIAGQLSRCEWREARVAK GDASRFWREDGVYVISGGTGALARLFVAEIGKRATRATVILVARASSAEAVDGGNGLRVRHLPVDVTQP NDVNAFVATVLREHGRIDGVIHAAGIRRDNYLLNKPVAEMQAVLAPKVVGLVNLDHATRELPLDFFVIF SSLAAFGNAGQSDYAAANGFMDGFAESRAALVNAGQRQGRIVSIRWPLWENGGMQLDSRSREVLMQR TGMAALGDEAGLGAFYRALELGSPGVAVWTGEAQRFRELSVSVSPAPPPHQVALDAVVSITEKVETKLK ALFSEVTRYEERRIDARQPMERYGIDSIIITQMNQALEGPYNALSKTLFFEYRILAEVSGYLAEHRAEESA KWVAAPGENSSSVIQEARPPRADATHRAPRADEPIAVIGMSGRYPGAENLTEFWERLSRGDDCITEIPPER WSLDGFFYPDKKHAAARGMSYSKWGGFLGGFADFDPLFFNISPREATSMDPQERLFLQSCWEVLEDAG YTRDSLAQRFGSAVGVFAGITKTGYELYGAELEGRDASVRPYTSFASVANRVSYLLDLKGPSMPVDTMC SASLTAVHMACEALQRGACVMALAGGVNLYVHPSSYVSLSGQQMLS

DNA sequence nucleotides 1-7178.

GTCGACCCGGCGAGGCTGACCCGGGCCTGGGAAGGACTGCTCGAACGGTATCCGCTGCTCGCTGGC GCGATTCGCGTCGAAGGCACGGAGCCGGTCATCGTCCCCAGTGGGCAGGTCTCCGCCGAGGTCCAC GAGGTTCCATCGGTCTCCGATTCAGCACTGGTGGCGACCCTGCGCGCCTCCGCGAAGGTGCCATTCG ATCTCGCCTGTGGACCGCTCGCTCGGCTGCACCTGTACTCGCGGTCGGAGCACGAGCATGTCCTGCT GCTGTGCTTCCACCACCTGGTGCTCGATGGGGCATCCGTGGCGCCCTTGCTCGACGCCCTCCGGGAG CGTTACGCCGGGACCGAGGCGAAGGCGGGGCTGCTCGAGGTTCCGATCGTCGCTCCTTACCGCGCC GCCGTGGAGTGGGAGCAGCTCGCCATTGGAGGCGATGAGGGACGGCGCCACCTCGACTACTGGCGG CACGTGTTGGCCACGCCGTTCCTCCGCCGTTGAATCTTCCAACGGACCGGCCTCGCTCCGCCACGG AGTTCGCTCGGGCACAGCAAGTGAGCCTGCCGACCGTCCTGCTCGGGCTCTACTACGCCTTGCTTCA TCGGCACACGCGCCAGGACGACGTGGTGGTCGGCATCCCCACCATGGGGCGGCCCCGGGCGGAACT GTTCGGCTCGCTGCGCCACCTCCACGACTCGGTCATCGATGGCCTGGAGCATGCCCACTATCCC TTCCCGCGAGTGGTGAAGGACCTCCGGCTGTCGAATGGGCCCGAGGAGGCGCCTGGCTTCCAGACG TTGCCGGAGCTTGAGCCGCTCGACTGCGTCCATCAGGAAGGCGCCTACCCGCTGGAGCTTGAAGTGG TGGAGGGCGCCAAGGGCCTCACGCTGCATTTCAAGTACGACGCGGGCTGTACGAGGCGGACACGG TCGAACGGATGGCGCGTCAGTTGTTGCGCGCCGCGGACCAGGTCGCGGATGGGGTGGAGTCTCCGC TGAGCGCACTGTCGTGGCTCGACGACGAAGAGCGCCGCACGCTTCTCCGCGACTGGAATGCCACGG CCACGCGTTCCTCGAGGACCTGGGCGTTCACGAGCTCTTCCAGCGGCAGGCCCGGGAGACCCCAG ACGCCATGGCTGTGAGCTACGAGGGGCACTCGCTCAGCTATCAGGCGCTGGATACGCGGAGCCGCG AGATTGCGGCGCACCTGAAGAGCTTCGGCGTCAAGCCTGGGGCGCTCGTGGGCATCTACCTGGACC GGTCCGCGGAGCTGGTGGCGGCGATGCTGGGTGTGCTGTCCGCTGGCGCGCCTACGTACCCCTGG ACCCGGTGCACCCCGAGGACCGGCTGCGGTACATGCTGGAGGACAGTGGCGTGGTGGTCGTGCTGG AGGACGTCAAGGCTGGAGCCACGTCCGCGCGGGGGGAACCTCACCGAACGGACTTGCCTACGTCA TCTACACGTCCGGGAGCACGGGCCGGCCCAAGGGCGTGATGATTCCCCATCGCGGGGTGGTCAACT TCCTCCTGTGCATGCGCAGGACGCTGGGCCTGAAGCGCACGGATTCGCTGTTGGCGGTCACGACGTA CTGCTTCGACATCGCGGCGCTCGAGCTCCTGCTTCCGCTGTGTGCGGGGGCGCAGGTCATCATCGCG TCGGCGGAGACGGTTCGGGATGCGCAGGCGTTGAAGCGGGCGCTGCGCACCCATCGGCCCACGTTG GACGTGTGGAACATGTTCGGGCCCACCGAGACGACCATCTGGTCGACGATGGCGAAGGTCTCGGCC TCGCGTCCGGTCACCATTGGAAAGCCGATCGACAACACGCAGGTCTACGTGCTGGACGACCGGATG CAGCCGGTGCCCATCGGTGTGCCGGGCGAGCTGTGGATTGCGGGCGCGGGCGTGGCCTGCGGTTAC CTCAACCGGCCGGCGCTGACCGCCGAGCGCTTCGTTTCCAATCCGTTCACGCCGGGCACGACGCTCT ACCGGACGGGGGACCTGGCGCGCGCGCGCGCGGTGAGGTTGAGTACCTGGGGCGGCTCGACC ACCAGGTGAAGGTGCGCGGCTTCCGCATCGAGATGGGGGAGATTGAAGCGCAGTTGGCCGGGCATC CCAGCGTGAAGAACTGTGCCGTGGTGGCCAAGGAGCTGAACGGCACCTCGCAGCTCGTCGCCTACT GTCAGCCGGGGGAACGAGCTTCGATGAGGAAGCCATCCGTGCACACCTGCGGAAGTTCCTCCCCG ACTACATGGTCCCCGCGCACGTCTTCGCGGTGGATGCGATTCCGCTGTCGGGCAATGGCAAGGTGGA CCGGGGCCAGCTGATGGCCAGGCCGGTGGTCACCCGGGGAAGACATCCGCGGTCCATGCCCGTTC

GGATCGCTTCTTCGAAGTGCGGGGGGGACTCCGTGCTGGCCGCCGTGCTGGTGGAGGAGATGAACCG GCGCTTCGACACGCGGCTCGCCGTCACCGACCTGTTCAAGTACGTCAATATTCGCGACATGGCGCGC CACATGGAGGGCGCGACGCGCAAGCCCGTACTGGGGCCACCGAGCCGGCTCGCGAGGACACCGCG TCGGAGCGTGACTACGAGGGCAGCCTGGCCGTCATCGGCATCTCCTGTCAGTTGCCCGGAGCCGCGG ACCCCTGGCGCTTCTGGAAGAACCTGCGAGAGGGCAGGGACAGCGTGGTGGCGTACCGCCATGAGG CATCGAAGACAAGGAGTGCTTCGACCCGCATTTCTTCGGTCTGACGGCGCGGGACGCGTCCTTCATG GACCCGCAGTTCCGACTGTTGCTGATGCACGCCTGGAAGGCAGTGGAAGACGCGGCGACGACGCCT GAGCGCCTGGGACCGTGCGGCGTCTTCATGACGGCCAGCAACAGCTTCTATCACCAGGGCTCGCCGC AATTTCCTGCGGACGGGCAGCCGGTCCTCCGCACCGCCGAAGAATACGTGCTGTGGGTGCTGGCCCA GGCAGGCTCCATCCCGACGATGGTTTCSTACAAGCTCGGCTTGAAGGGGCCGAGCCTGTTCGTCCAC ACCAACTGCTCGTCATCCCTGTCCGCGCTGTACGTGGCTCAGCAGCCATCGCAGCGGGAGACTGCC AGACGGCGCTGGTGGGGGCCGCCACGGTCTTCCCTTCGGCGAACTTGGGTTATCTGCACCAGCGGG GGCTCAACTTCTCCAGCGCGGGGCGGGTCAAGGCCTTCGACGCCGGGGGGGACGGCATGATTGCCG GTGAAGGTGTCGCCGTGCTGGTGAAGGACGCCGCAGCGGCGGTGCGCGATGGCGACCCAATCT ACTGCCTCGTGCGGAAGGTGGGGATCAACAACGACGGCCAGGACAAGGTGGGTTTATACGCCCCGA GCGCCACCGGGCAGGCGAGGTCATCCGGCGTCTGTTCGACCGGACCGGCATCGACCCTGCATCGA TTGGCTACGTCGAGGCCCATGGCACCGGAACCTTGCTGGGTGACCCTGTCGAGGTCTCCGCGCTGAG CGAAGCCTTCCGGACCTTCACCGACCGGCGCGGGTACTGCCGGCTGGGCTCGGTGAAGTCGAACCT GGGCCATCTGGACACAGTGGCTGGACTGGCTGAGCTCATCAAGACGGCGCTGAGCCTGCGGCAGGG CGAAGTTCCTCCGACGCTCCATGTGACCCAGGTGAATCCGAAGCTCGAGCTGACGGATTCGCCGTTC TTCGGCCTTGGCGGGACGAATACCCACGCCATTCTCGAACACTACCCGCGCGACTCCCGCCCACGGG AGAGGAGCCAGCGGTCGAACGCAGTCCGTGCGGTGGCTCCATTCTCGGCGCGCACCCTGGAGGCGT TGAAGGACAACCTCCGCGCGCTCCTCGACTTCCTGGAGGACCCGGCGTCCGCGGAGGTGGCGCTCG CGGACATCACCTACACGTTGCAGGTCGGCCGGGTCGCGATGCCTGAGCGGATGGTGACTGCGT CGACGCGCGACGAATTGGTGGAGGGACTGCGGGGGGGGGAGGCATCGCGACGGTGGGCGGTGCCCACGTGG GAACGGTGGTCGATACGTCACCCAGCGTGGATGCCGATGCTCGGGCAGTTGCGGAGGCGTGGGCGA GTATCAGTTCGCGAAGGAGCGCTACGGGTTGTCGCCCGCGCACTCCGTGGCGAATTCCTCCAAGACG CATCCTGACGCGGTGTCCCGCTCTTCGTTCCGACCTGGCAGCCGTGGTCTGAGGGCGCGTCAAATG CCTCGTTGGCGCTCCGGCACCTGGTGGTGTTGTGCGAGCCTCTTGATGCGCTGGGGGCTGAAGGTGC CTCCGCGCTGGCGAGCACGCTCGCGGACAGCGCATCGAAGTGGTCAGGACGTCCAGCCCAAGTGC GCGGCTGGACGCGCGGTTCATGGCGCATGCCTCGGCGGTCTTCGAACGCGTCAAGGCGCTGCTGTCG GAGCGTCTGACCGCTCCTGTGACATTGCAGGTGCTGGTGCCAGAGGAGCGGGATGCGCTGGCACTG AGTGGCCTGGGGAGCCTGCTGCGTTCGGTGTCGCAGGAGAATCCGTTGGTCCGGGGGCAGCTCATC GACGTCACCGATTCGCGGTACCACGCGGGCCAGCTTTCTCGCTGTGAGTGGCGCGAGGCACGTGTCG CCAAGGGGGACGCATCCCGCTTCTGGCGCGAAGACGGCGTCTATGTGATTTCAGGAGGAACCGGCG CCCTGGCCGGCTGTTCGTCGCCGAAATCGGGAAGCGCGCGACGCGGGCCACCGTCATTCTGGTTGC CCGCGCATCCTCGGCGGAGGCGGTGGACGGTGGGAACGGGCTGCGCGTGCGCACCTTCCCGTGGA TGTCACCCAACCGAACGACGTGAACGCCTTTGTCGCTACGGTGCTGCGCGAACACGGGCGCATCGAC GGTGTCATCCATGCGGCGGCATCCGCCGTGACAACTACCTGCTCAACAAGCCGGTGGCGGAAATG CAGGCGGTGCTCGCGCCCAAGGTGGTGGGGCTCGTCAACCTGGACCACGCCACCCGCGAGCTGCCC CTGGATTTCTTCGTCACGTTCTCGTCCCTGGCCGCGTTTGGAAACGCCGGTCAGTCGGACTACGCGG CGGCCAATGGCTTCATGGACGGATTCGCGGAGTCCCGAGCGGCGCTCGTGAACGCCGGACAGCGGC AGGGCCGGACGGTGTCCATCCGTTGGCCGCTCTGGGAGAACGGCGGGATGCAGCTCGACTCACGGA GCCGTGAGGTCTTGATGCAGCGGACCGGGATGGCCGCGCTGGGAGACGAAGCGGGACTGGGGGCGT TCTACCGGGCGCTGGAACTGGGCTCCCCTGGTGTCGCGGTGTGGACGGGGGAGGCCCAGAGGTTTC GTGAACTCTCCGTGAGTGTTTCGCCCGCACCGCCTCCGCATCAGGTGGCGTTGGACGCCGTGGTGTC CATCACCGÁGAAGGTCGAGACGAAGCTGAAGGCGCTCTTCAGCGAGGTCACGCGATACGAAGAGCG CCGCATCGATGCCCGCCAGCCGATGGAGCGCTATGGCATCGACTCCATCATCACGCAGATGAAC CAAGCCCTCGAAGGCCGTACAACGCCCTCTCGAAGACGCTGTTCTTCGAATACCGGACGCTCGCGG GAGAATTCGTCTTCCGTCATCCAGGAGGCCA'GGCCGCCACGTGCGGATGCGACGCACCGGGCGCCT CGCGCCGACGAGCCCATCGCCGTCATTGGCATGAGCGGCCGTTATCCCGGGGCGGAGAACCTGACG GAGTTCTGGGAGCGCCTGAGCCGCGGTGACGACTGCATCACCGAGATTCCGCCAGAGCGCTGGTCG GGCGGCTTCCTCGGCGGCTTCGCTGACTTCGACCCGCTGTTCTTCAACATCTCGCCGCGTGAGGCGA CGAGCATGGACCCGCAGGAGCGCTTGTTCCTGCAGAGCTGCTGGGAGGTCCTGGAGGACGCGGGGT ACACCCGGGACAGCCTGGCCCAGCGCTTTGGCAGCGCGTGGGCGTTTTCGCGGGAATCACGAAGA CGGGCTACGAACTCTACGGCGCGGAGCTGGAAGGACGAGATGCCTCGGTCCGGCCCTATACGTCGT TTGCGTCTGTTGCCAACCGCGTCTCGTATCTGCTCGACCTGAAGGGGCCGAGCATGCCCGTGGACAC CATGTGCTCGGCCTCGCTGACAGCCGTCCACATGGCTTGCGAGGCGCTGCAACGAGGCGCCTGCGTC

ATGGCCATCGCGGGTGGAGTGAATCTCTACCTCCACCGGTCGAGCTACGTCAGCCTGTCCGGGCAGCAGATGCTGTCGAC

REGION 2

TaR1 - Surface layer protein

From nucleotide 2955 to 601, size(22): 785.

MKVVNKLLEKLPDVVAGKVPDVKLQDQDIKVPLAQGTFTEEKILPPKLAMHGFTLSFEATGEASIRNFNS LGDVDENGIIGEPSPESAEPGPRPQLLLGSDIGWMRYQVSARVKAAVSASLSFLASENQTELSVTLSDYRA HPLGQNMREAVRSDLSELRLMQATDLAKLTTGDAVAWHVRGALHTRLELNWADIFPTNLNRLGFLRGN ELLALKTSAKAGLSARVSLTDDYQLSFSRPRAGRIQVAVRKVKSHEQALSAGLGITVELLDPATVKAQLG ELLALKTSAKAGLSARVSLTDDYQLSFSRPRAGRIQVAVRKVKSHEQALSAGLGITVELLDPATVKAQLG QLLEALLGPVLRDLVKKGTTAVEIMDGLVDKASKAKLDDNQKKVLGLVLERLGIDPQLADPANLPQAW ADFKARVAESLENAVRTQVAEGFEYEYLRLSETSTLLEVVVEDVTAMRFHESLLKGNLVELLKWMKSLP AQQSEFELRNYLHATTLTRQQAIGFSLGLGSFELLKAKNVSKQSWVTQENFQGARRMAFLGRRGYEDKL LGTRGQWVVDLKADMTRFSPTPVASDFGYGLHLMLWGRQKKLSRKDLQQAVDDAVVWGVLDAKDA ATVISTMQEDMGKHPIETRLELKMADDSFRALVPRIQTLELSRFSRALARALPWSEQLPRASAEFRRAVY APIWEAYLREVQEQGSLMLNDLSPSRAAQIAKWYFQKDPTVRDLGKDLQLIESEWRPGGGNFSFAEVIS KNPNTLMRCRNFVSGMVRLRRAIDERKAPDELRTVFGELEGMWTTGFHLRAAGSLLSDLÁQSTPLGLAG VERTLTVRVADSEEQLVFSTARSTGAA

TaR2 - two component system, response regulator

From nucleotide 3116 to 4702, size(22): 529.

MPSGCYGAASAFVLPPLPAMPQAPSDVSQVLLPFGGLVGREVDLDAFLQTLMDRIAITLQADRGTLWLL DPARRELFSRAAFILPEVSQIRVKLGQGVAGTVAKAGHAINVPDPRGEQRFFADIDRMTGYRTTSLLAVPL RDGDGALYGVLQVLNRRGEDRFTDEDTQRLTAIASQVSTALQSTSLYQELQRAKEQPQVPVGYFFNRIIG ESPQLQAIYRLVRKAAPTDATVLLRGESGSGKELFARAVHVNGPRRDQPFIKVDCAALPATLIENELFGH ERGAFTGADHRVPGKFEAASGGTVFIDEIGELPLPVQGKLLRVIQDREFERVGGTQAVKVDVRIVAATHR DLARMVAEGRFREDLYYRIKVVEVVLPPLRERGAEDIERLARHFVAAVARRHRLTPPRLSAAAVERLKR YRWPGNVRELENCIESAVVLCEGEILEEHLPLPDVDRAALPPPAAAQGVNAPTAPAPLDAGLLPLAEVER RHILRVLDAVKGNRTAAARVLAIGRNTLARKLKEYGLGDEP

TaR3 - two component system, kinase sensor.

From nucleotide 5595 to 4720. size(aa): 292

MRASQAEAPHSRRLTMEVRFHGVRGSIAVSGSRIGGNTACVEVTSQGHRLILDAGTGIRALGEIMMREG APQEATLFFSHLHWDHVQGFPFFTPAWLPTSELTLYGPGANGAQALQSELAAQMQPLHFPVPLSTMRSR MDFRSALHARPVEVGPFRVTPIDVPHPQGCLAYRLEADGHSFVYATDVEVRVQELAPEVGRLFEGADVL CLDAQYTPDEYEGRKGVAKKGWGHSTMMDAAGVAGLVGARRLCLFHHDPAHGDDMLEDMAEQARA LFPVCEPAREGQRLVLGRAA

TaA - NUS-G like transcription antiterminatior.

From nucleotide 6290 to 6793, size(a2): 168

MPGPRCAENDWVALLVRVNHEKVAAAQLGKHGYEFFLPTYTPPKSSGVKAKLPLFPGYLFCRYQPLNP YRIVRAPGVIRLLGGDAGPEAVPAQELEAIRRVADSGVSSNPCDYLRVGQRVRIIEGPLTGLEGSLVTSKS QLRFIVSVGLLQRSVSVEVSAEQLEPITD 2290.00075

TaB - acyl carrier protein (ACP).

From nucleotide 6870 to 7106, size(aa): 79

MDKRIIFDIVTSSVREVVPELESHPFEPEDDLVGLGANSLDRAEIVNLTLEKLALNIPRVELIDAKTIGGLV DVLHARL

TaC - beta-ketoacvi [ACP] synthase III (KAS III, FabH)

From nucleotide 7119 to 8378, size(aa): 420

MGPVGIEAMNAYCGIARLDVLQLATHRGLDTSRFANLLMEEKTVPLPYEDPVTYGVNAARPILDQLTAA ERDSIELLVACTESSFDFGKAMSTYLHQHLGLSRNCRLIELKSACYSGVAGLQMAVNFILSGVSPGAKAL VVASDLSRFSIAEGGDASTEDWSFAEPSSGAGAVAMLVSDTPRVFRVDVGANGYYGYEVMDTCRPVAD SEAGDADLSLLSYLDCCENAFREYTRRVPAANYAESFGYLAFHTPFGGMVKGAHRTMMRKFSGKNRGD IEADFQRRVAPGLTYCQRVGNIMGATMALSLLGTIDHGDFATAKRIGCFSYGSGCSSEFFSGVVTEEGQQ RQRALGLGEALGRRQQLSMPDYDALLKGNGLVRFGTRNAELDFGVVGSIRPGGWGRPLLFLSAIRDFHR DYQWIS

TaD - membrane associated protein

From nucleotide 8404 to 9378, size(aa): 325

MSSVATAVPLTARDSAVSRRLRITPSMCGQTSLFAGQIGDWAWDTVSRLCGTDVLTATNASGAPTYLAF YYFRIRGTPALHPGALRFGDTLDVTSKAYNFGSESVLTVHRICKTAEGGAPEADAFGHEELYEQPQPGRI YAETFNRWITRSDGKSNESLIKSSPVGFQYAHLPLLPDEYSPRRAYGDARARGTFHDVDSAEYRLTVDRF PLRYAVDVIRDVNGVGLIYFASYFSMVDWAIWQLARHQGRSEQAFLSRVVLDQQLCFLGNAALDTTFDI DVQHWERVGGGFELFNVKMREGAQGRDIAVATVKVRFDAASEGGRRG

TaE - acvi carrier protein (ACP).

From nucleotide 9386 to 9364, size(2a): \$2

MTDEQIRGVVHQSIVRVLPRVRSNEIAGHLNLRELGADSVDRVEILTSILDSLRLQKTPLAKFADIRNIDAL VAFLAGEVAGG

TaF - beta-ketoacyl [ACP] synthase III (KAS III. FabH)

From nucleotide 9757 to 10878, size(aa): 374

MMQERGVALPFEDPVTNAVNAARPILDAMSPEARERIELLVTSSESGVDFSKSISSYAHEHLGLSRHCRFL EVKQACYAATGALQLALGYIASGVSPGAKALVIATDVTLVDESGLYSEPAMGTGGVAVLLGDEPRVMK MDLGAFGNYSYDVFDTARPSPEIDIGDVDRSLFTYLDCLKHSFAAYGRRVDGVDFVSTFDYLAMHTPFA GLVKAGHRKMMRELTPCDVDEIEADFGRRVKPSLQYPSLVGNLCSGSVYLSLCSIIDTIKPERSARVGMF SYGSGCSSEFFSGVIGPESVSALAGLDIGGHLRGRRQLTFDQYVELLKENLRCLVPTKNRDVDVERYLPL VTRTASRPRMLALRRVVDYHRQYEWV

TaG - signal peptidase II (LSPA)

From nucleotide 10909 to 11421, size(aa): 171

2290.00075

MNTPSLTNWPARLGYLLAVGGAWFAADQVTKOMARDGAKRPVAVFDSWWHFHYVENRAGAFGLFSS FGEEWRMPFFYVVGAICIVLLIGYYFYTPFTMKLQRWSLATMIGGALGNYVDRVRLRYVVDFVSWHVG DRFYWPSFNIADTAVVVGAALMILESFREPRQQLSPG

TaH - cytochrome P450 hydroxylase (cP450)

From nucleotide 11473 to 12897, size(aa): 475

MGTSEPVEPDHALSKPPPVAPVGAQALPRGPAMPGIAQLMMLFLRPTEFLDRCAARYGDTFTLKIPGTPP FIQTSDPALIEVIFKGDPDLFLGGKANNGLKPVVGENSLLVLDGKRHRRDRKLIMPTFLGERMHAYGSVI RDIVNAALDRWPVGKPFAVHEETQQIMLEVILRVIFGLEDARTIAQFRHHVHQVLKLALFLFPNGEGKPA AEGFARAVGKAFPSLDVFASLKAIDDIIYQEIQDRRSQDISGRQDVLSLMMQSHYDDGSVMTPQELRDEL MTLLMAGHETSATIAAWCVYHLCRHPDAMGKLREEIAAHTVDGVLPLAKINELKFLDAVVKETMRITP VFSLVARVLKEPQTIGGTTYPANVVLSPNIYGTHHRADLWGDPKVFRPERFLEERVNPFHYFPFGGGIRK CIGTSFAYYEMKIFVSETVRRMRFDTRPGYHAKVVRRSNTLAPSQGVPIIVESRLPS

TaI - malonyl CoA [ACP] transacylase (MCT, FabD)

From nucleotide 12938 to 13891, size(aa): 318

MVDSVSKQARRKVFLFSGQGTQSYFMAKELFDTQTGFKRQLLELDEQFKQRLGHSILERIYDARAARLD PLDDVLVSFPAIFMIEHALARLLIDRGIQPDAVVGASMGEVAAAAIAGAISVDAAVALVAAQAQLFARTA PRGGMLAVLHELEACRGFTSVARDGEVAAINYPSNFVLAADEAGLGRIQQELSQRSVAFHRLPVRYPFHS SHLDPLREEYRSRVRADSLTWPRIPMYSCTTANRVHDLRSDHFWNVVRAPIQLYDTVLQLEGQGGCDFI DVGPAASFATIIKRILARDSTSRLFPLLSPSPASTGSSMG

TaJ - malonyl CoA [ACP] transacylase (MCT, FabD)

From nucleotide 13909 to 14898, size(aa): 330

MTEAPAPRAPAQVPPPPSSPWALHTRGAASAPVNARKAALFPGQGSQERGMGAALFDEFPDLTDIADAI LGYSIKRLCLEDPGKELAQTQFTQPALYVVNALSYLKRLREGAEQPAFVAGHSLGEYNALLVAGAFDFE TGLRLVKRRGELMSGASGGTMAAVVGCDAVAVEQVLRDRQLTSLDIANINSPDQIVVSGPAQDIERARQ CFVDRGARYVPLNVRAPFHSRYMQPAASEFERFLSQFQYAPLRCVVISNVTGRPYAHDNVVQGLALQLR SPVQWTATVRYLLEQGVEDFEELGPGRVLTRLITANKRGAPAPATAAPAKWANA

TaK - 3-oxoacyl [ACP] synthase (KAS I, FabB)

From nucleotide 14963 to 16213, size(aa): 417

MSTSPVQELVVSGFGVTSAIGQGAASFTSALLEGAARFRVMERPGRQHQANGQTTAHLGAEIASLAVPE GVTPQLWRSATFSGQAALVTVHEAWNAARLQAVPGHRIGLVVGGTNVQQRDLVLMQDAYRERVPFLR AAYGSTFMDTDLVGLCTQQFAIHGMSFTVGGASASGLLAVIQAAEAVLSRKVDVCIAVGALMDVSYWE CQGLRAMGAMGTDRFAREPERACRPFDRESDGFIFGEACGAVVVESAEHARRRGVTPRGILSGWAMQL DASRGPLSSIERESQVIGAALRHADLAPERVDYVNPHGSGSRQGDAIELGALKACGLTHARVNTTKSITG HGLSSAGAVGLIATLVQLEQGRLHTSLNLVDPIDSSFRWVGATAEAQSLQNALVLAYGFGGINTAVAVR RSATES

TaL - enoyl CoA hydratase.

From nucleotide 16224 to 17009, size(aa): 262

MQAASPPHRDYQTLRVRFEAQTCFLQLHRPDADNTISRTLIDECQQVLTLCEEHATTVVLEGLPHVFCM GADFRAIHDRVDDGRREQGNAEQLYRLWLQLATGPYVTVAHYQGKANAGGLGFVSACDIVLAKAEVQ FSLSELLFGLFPACVMPFLARRIGIQRAHYLTLMTRPIDAAQALSWGLADAVDADSEKLLRLHLRRLRCLS KPAVTQYKKYASELGGQLLAAMPRAISANEAMFSDRATLEAIHRYVETGRLPWES 2290,00075

TaM - enovi CoA hydratase.

From nucleotide 17000 to 17767, size(aa): 256

MGIMTEGTPMAPVVTLHEVEEGVAQITLVDRENKNMFSEQLVRELITVFGKVNGNERYRAVVLTGYDT YFALGGTKAGLLSICDGIGSFNVTNFYSLALECDIPVISAMQGHGVGGGFAMGLFADFVVLSRESVYTTN FMRYGFTPGMGATYIVPKRLGYSLGHELLLNARNYRGADLEKRGVPFPVLPRKEVLPHAYEIARDLAAK PRLSLVTLKRHLVRDIRRELPDVIEREI.EMHGITFHHDDVRRRIEQLFL

TaN - O-methyltransferase (fragment)

From nucleotide 17782 to 19053, size(aa): 423

MLNLINNHAHGYVVTPVVLACNDAGLFELLRQGPKDFDRLAEALRANRGHLRVAMRMFESLGWVRRD ADDVYAVTAAAAAHRSFPREAQSLFALPMDRYLRGEDGLSLAPWFERSRASWDTDDTLVRELLDGAITT PLMLALEQRGGLKEARRLSDLWSGGDGRDTCVPEAVQHELAGFFSAQKWTREDAVDAELTPKGAFIFE RALLFAIVGSYRPMLASMPQLLFGDCDQVFGRDEAGHELHLDRTLNVIGSGHQHRKYFAELEKLITVFD AENLSAQPRYIADMGCGDGTLLKRVYETVLRHTRRGRALDRFPLTLIAADFNEKALEAAGRTLAGLEHV ALRADVARPDRLIEDLRARGLAEPENTLHIRSFLDHDRPYQPPADRAGLHARIPFDSVFVGKAGQEVVPAEVFHSLVEHLE

DNA sequence 1-19053

GTCGACGTTGACGTCGCCCGGTGGCGTGCCGTGTCTTCTTCGACGCGGAGGTGCGCGAGGTGGCG GCGGACGGCCGGCGCGCGCTGTTGTCGCGTGAGCGCGCGTATGCGCCGGTACTGGCGCTGCGT GGCCAGCGCCTCCATGCTTCGGTGTCCTTTTCGCCCGCGTCGCTGATGGCTCCGGTGGAGGTGCGCC GGTGCAAGGCCCTGCCAGGCACGGTGCCCGCGTCCTGGTATCAGACGGCGCACCCGGAGGCCCTGT TCGAGGGCAGCTACGCCCTGGTCGGTCGGGAGGGCGGCCCCGCGATGTTGGTGCTGGGACCCCAGG CTCCGGCCACCTGTGGGACGCTGGCGCGCGGGCCTGGCGGCACTTCGCGGCGGCCGGGTGCTGT CCATGGCCGCGGCCGTCCTCTCAGGGGCGCTGTGAGACGCGCGGGGGGCCGTACCGCCGC CCAGAAACGTGATGCGCCGCCAGGCCTCGCGGTCCGGGCACTGACGCCCGGGCCGCTCGGGACTCG CTCAGGCGGCTCCGGTGCTTCGCGCGGTGGAGAACACGAGCTGTTCCTCGCTGTCCGCCACCCGCAC GGTGAGGGTCCGCTCCACGCCGGCGAGGCCCAGCGCGTGGACTGCGCCAGGTCCGAGAGCAGGGA GCCCGCAGCGCGCAGGTGGAAGCCGGTGGTCCACATGCCCTCCAGCTCGCCGAACACGGTGCGCAG CTCGTCCGGGGCCTTGCGTTCGTCGATGGCGCGGCGCAGGCGCACCATGCCGCTCACGAAGTTCCTG CACCGCATGAGCGTGTTGGGGTTCTTGGAGATGACCTCCGCGAAGCTGAAGTTGCCGCCACCCGGGC GCCACTCGCTTCGATGAGCTGCAGGTCCTTGCCAAGGTCGCGCACCGTGGGGTCCTTCTGGAAGTA CCACTTGGCGATCTGCGCGGCGGGCTGGGTGACAAGTCATTCAGCATGAGGCTGCCTTGCTCCTGC GGAAGCTGCTCGCTCCAGGGCAGCGCGCGGGCCAGGGCGCGTGAGAAGCGGGACAGCTCGAGCGTC TGGATGCGGGGCACCAGGGCGCGGAACGAGTCATCCGCCATCTTCAGCTCGAGCCGCGTTTCGATG GGGTGCTTGCCCATGTCCTCCTGCATGGTGCTGATGACGGTGGCCGCGTCCTTCGCGTCCAGCACGC CCCAGACGACGCGTCATCCACCGCCTGCTGCAGGTCCTTGCGCGACAGCTTCTTCTGCCGTCCCCA CAGCATCAGGTGCAGGCCGTAGCCGAAGTCGGAGGCCACGGGGGTGGGAGAGAAGCGCGTCATGTC CGCCTTCAGGTCCACCACCCACTGGCCGCGGGTGCCCAGCAGCTTGTCCTCGTAGCCCCGGCGTCCG TCGCCTTGAGCAGCTCGAACGAGCCCAGCCCCAGTGAGAAGCCGATGGCCTGCTGGCGCGTGAGCG TGGTGGCGTGCAGGTAGTTGCGCAGCTCGAACTCGCTCTGCTGGGCGGGGAGGCTCTTCATCCACTT CAGCAGCTCCACCAGGTTGCCCTTGAGCAGGGACTCGTGGAAGCGCATCGCGGTGACGTCCTCCACG ACGACCTCCAGCAGCGTGGAGGTCTCCGACAGGCGCAGGTATTCGTACTCGAAGCCCTCGGCGACCT GCGTGCGGACGCGTTCTCCAGCGACTCTGCGACGCGGGCCTTGAAGTCGGCCCAGGCCTGCGGAA GGTTGGCCGGGTCCGCAAGCTGCGGGTCGATGCCAAGGCGCTCCAGCACCAGGCCCAGCACCTTCTT CTGATTGTCGTCCAGCTTCGCCTTGCTGGCCTTGTCCACCAGGCCGTCCATGATTTCCACCGCGGTGG TGCCCTTCTTGACGAGGTCGCGAAGGACGGGCCCCAGCAGCGCTTCCAGCAACTGGCCCAGTTGGG CCTTCACCGTCGCCGGGTCCAGCAGCTCCACGGTGATGCCCAGGCCGGCGGAGAGCGCCTGCTCATG GGACTTCACCTTGCGCACGGCGACCTGGATGCGGCCGGCACGGGGACGGGAGAAGCTGAGCTGGTA GTCGTCGGTGAGGGACACCCGGGCGGACAGGCCCGCCTTGGCGCTGGTCTTCAACGCGAGCAGCTC

E ()

GTTGCCGCGCAGGAAGCCCAGGCGGTTGAGGTTGGTGGGGAAGATGTCCGCCCAGTTGAGCTCCAG CCGTGTGTGGAGCGCCGCGGACATGCCACGCCACCGCGTCCCCGTGGTCAGCTTGGCCAGGTCG GTGGCCTGCATCAGCCGCAGCTCGGACAGGTCGGAGCGCACGGCCTCACGCATGTTCTGGCCCAGC AGGCTGGCGCTCACGGCGCCTTCACGCGCGCGGACACCTGGTAGCGCATCCACCCGATGTCACTGC CCAGCAGCAGTTGGGGCCGGGGCCCTGGCTCGGCGCTCCGGGCTCGGCCGATGATGCCGTT TTCGTCCACGTCGCCCAGCGAGTTGAAGTTCCGGATGGACGCTTCGCCGGTGGCTTCGAAGGAGAG GGTGAAGCCGTGCATGGCGAGCTTGGGCGGAAGGATTTTCTCTTCCGTGAAGGTCCCCTGGGCCAGC GGCACCTTGATGTCCTGGTCCTGCAGCTTCACGTCGGGCACCTTGCCCGCCACGACGTCGGGAAGCT TCTCCAGCAGCTTGTTGACCACTTTCATGCGCGTCCCCCTGGGCTGAAGCCTCCTGCACGTGGGCCG GAGGTCTCTTCGTCGTACGCCGTTGCCCAGCTCGGAACAAGGCGGATACCAGAAAAGACCGGTGGT CAGCGGACAGATGCCCTGGAGGGTGGGGTGGGAGCCGCCCCGCGCGGTGCGTCAGGGCTCGTCGC CCAATCCGTACTCCTTGAGTTTCCGCGCGAGCGTGTTGCGGCCAATCGCCAGCACGCGGGCCGCGC GGTGCGGTTGCCCTTCACGCCGTCCAGCACGCGCAGGATGTGGCGGCGTTCGACCTCCGCCAGTGGC AGCAGGCCCGCATCCAGGGGCGCAGGCGCAGTCGGCGCTTGACCCCTGAGCGGCTGCGGGAGGC GGCAGGGCGGCCCGGTCCACATCGGGCAGGGCAGGTGCTCTTCGAGAATCTCCCCTTCACAGAGC ACCACGGCGCTCTCGATACAGTTCTCCAGCTCCCGCACGTTTCCGGGCCAGCGGTAGCGCTTGAGGC GCTCCACCGCGCGCGCTGAGCCGGGCGCGCCTCAGCCGGTGCCTCCGGGCGACGGCGACGA AGTGGCGGGCGAGCCGCTCGATGTCCTCCGCGCCGCGCTCCCGCAGCGCGGCAGCACCACCTCGA CCACCTTGATGCGGTAGTAGAGGTCCTCGCGGAAGCGGCCCTCGGCCACCATGCGGGCCAGGTCCC GATGGGTGGCCGCGACGATGCGCACGTCCACCTTCACGGCCTGGGTGCCTCCCACGCGCTCGAACTC GCGATCCTGGATGACCCGCAGCAACTTGCCCTGCACCGGCAGGGGCAGCTCGCCAATCTCGTCGATG AACACGGTGCCGCCGCTGGCCGCTTCGAACTTGCCGGGCACGCGGTGGTCCGCCGCCGGTGAAGGCG TGAAGGGCTGGTCCCTGCGGGGACCATTCACGTGGACGGCACGGCGAACAGCTCCTTGCCGCTGC CACTCTCGCCGCGCAGCAGCACCGTCGCATCGGTGGGCGCGCCTTGCGCACCAGTCGGTAGATGG CCTGGAGCTGCGGGACTCGCCGATGATGCGGTTGAAGAAGTAGCCCACCGGTACCTGGGGCTGCT GGCGGTGAGCCGCTGCGTGTCGTCGGTGAAGCGGTCCTCGCCGCGGCGGTTGAGGACCTGGAG CACGCCGTAGAGGGCGCCGTCCCCGTCGCGCAGTGGCACGCGAGCAGCTGGTGGTGCGGTAGCC CGTCATCCGGTCGATGTCCGCGAAGAAGCGCTGCTCGCCGCGCGGGTCCGGCACGTTGATGGCGTG CCCGCCTTGGCGACGGTGCCGGCGACGCCCTGGCCCAGCTTGACGCGAATCTGGGACACCTCGGGC AGGTGCGCGCGCGCTGAACAGCTCGCGGCGGGCCGGGTCCAGCAGCCAGAGCGTGCCGCGGTCC GCTTGCAGGGTGATGGCGATGCGGTCCATCAGCGTCTGGAGGAACGCGTCGAGGTCCACCTCCCTG CCGACGAGTCCTCCGAAGGGGAGGAGGACCTGGGAGACGTCCGAGGGGGCTTGGGGCATGCCGG CAACGCCGCAGGACGAAGGCGGAGGCCGCACCATAACATCCAGAGGCATGGGACTGCCCCCTCT CAGGCCGCGCGCCCAGCACCAGCCGCTGGCCTTCGCGTGCGGGCTCGCACACGGGGAAGAGGGCG CGGGCCTGCTCCGCCATGTCCTCGAGCATGTCGTCGCCGTGCGCCGGGTCATGGTGGAACAGGCACA CTTCGCCACGCCCTTGCGGCCTCGTATTCGTCCGGCGTGTACTGCGCATCCAGGCACAGGACGTCC GCGCCTCGAAGAGGCGCCCACCTCCGGCGCGAGCTCCTGCACCCGCACCTCCACGTCCGTGGCGT AGACGAACGAATGGCCATCCGCCTCCAGGCGGTACGCCAGGCACCCCTGCGGGTGCGGCACGTCGA TGGGCGTGACGCGGAAGGGGCCCACCTCCACGGGTCGGGCATGCAACGCCGAGCGGAAGTCCATCC GCGAGCGCATGGTGCTCAGCGGCACCGGAAAATGAAGCGGCTGCATCTGCGCGGCCAACTCGGACT GGAGCGCCTGGGCCCATTCGCGCCCGGACCGTAGAGCGTCAGCTCGGACGTGGGCAGCCAGGCCG GCGTGAAGAAGGGGAAGCCCTGCACGTGGTCCCAATGCAGATGCGAGAAGAAGAAGCGTGGCCTCCT GGGGCGCCCCCGCGCATCATGATTTCGCCCAGTGCGCGGATGCCCGTCCCCGCATCCAGGATGAG GCGGTGGCCCTGGCTGGTCACCTCCACGCAGGCCGTGTTGCCACCAATGCGCGAGCCCGACACCGCG ATGCTCCCCGAACGCCATGAAACCGGACTTCCATCGTAAGTCTCCTTGAATGGGGGGCCTCCGCCT GGGACGCCTCATGCCCGGAGCCTCAGAGCACGGGGTGTGCCATTCCCAAATGCCCGGAATCAGGA GCGCGGCCTCGGCCTCCACCGGTGCTCCAGAATGGATCGCGCTCGCCTGGTGCGGGCGATCCA AAGCGGTGCAGGTCGCCCGCAGGACGGGGGGGGGGCACGTCTTCCAACGTCCCACGGCAGTCCTG TCTTCAGATCTCTCCCGATGCGGGAAGGCGTCCAGGAGGTTGCACCCGGCATCGAGCGGGCTGTGT GTTTCAAGTCTTGTCGGAGCCTCGGACACACCGTCTGGGTTCTGGGAATGCGCCGGCTTCCGTTCA CTCCAGAGTGATTCAATGGCTCTCGAGTGCAGGTTTAGCAATCCTCGGGCCGTAACCACGCCGTTGA AGGCAGTCACGCTCTCGTCACGCTTGGGGTGTTTCCAGCTTCAACGGTGTTTATCCTTCAGGGCGGT TTGCTTGACACGCTGCCTCATGGAAGCGTATGCAAAACAATGAAAACGGTGTCGTTGCCGAGCCTTA GGGCCTCCAGAACGCCATCCTCGCGGACCCAGGCAGCCGGAATTTGAGACGGGGCTGTCAGCGGTT TGAACGCAAGGATGCGGGGGGGTTGTGGCGGCAGCCCGACCAGAATTCGGTTGGTGTGCCAGTTA TTGTCAGATTCTGAGAAATAGCAGGCTGGGGGGAAGTTGCAATGCCTGGGCCGCGGTGTGCTGAGA ACGATTGGGTTGCATTGCTCGTCCGCGTCAATCACGAGAAAGTGGCTGCCGCTCAGTTGGGGAAACA CGGCTACGAGTTCTTCCTGCCGACGTACACGCCTCCCAÁGTCCTCGGGTGTGAAGGCGAAGCTTCCG CTCTTCCCCGGGTACCTTTTCTGTCGTTACCAGCCGCTCAATCCGTACCGCATCGTCCGGGCCCCGG GGTCATCCGGCTGCTCGGAGGTGACGCGGGGCCGGAAGCCGTGCCCGCACAGGAATTGGAGGCCAT

()

CCGCCGGGTCGCGGATTCGGGTGTCTCTTCCAATCCCTGTGACTATCTGCGGGTGGGGCAGCGCGTG CGCATCATCGAAGGGCCCCTGACAGGTCTGGAAGGAAGTCTGGTGACGAGCAAGAGCCAACTCCGG TTCATTGTCTCCGTGGGGCTGCTACAGCGCTCGGTGTCCGTGGAGGTGAGCGCCGAGCAACTGGAAC CGATCACCGACTGATTCCGCGGACATCCCCTTCCATTCCTTCATCACCCCGACCCGCAGCAAGGCTTC AGGGACCGTGAGTCGTTCCATGGACAAGAGAATTATTTTCGACATCGTCACCAGCAGTGTTCGGGAG GTGGTACCCGAACTCGAATCACATCCGTTCGAGCCGGAGGATGACCTGGTCGGACTGGGCGCGAAC TCGCTCGACCGCGCGAAATCGTCAACCTCACGCTGGAGAAGCTGGCGCTCAACATCCCCGGGTCG AGCTGATTGACGCGAAGACCATTGGCGGGCTGGTGGACGTCCTTCACGCGAGGCTGTGAGGCGAAG CCATGGGGCCGGTCGGGATTGAAGCCATGAATGCCTACTGTGGCATCGCCAGGTTGGATGTGTTGCA GCTGGCGACCCACCGTGGCCTGGACACCTCCCGCTTCGCGAACCTGCTCATGGAGGAGAAGACCGTC CCGCTCCCTATGAGGACCCTGTCACCTACGGCGTGAATGCCGCCCGGCCCATCCTGGACCAGTTGA CCGCGGCGGAACGGACAGCATCGAGCTGCTGGTGGCTTGCACGGAGTCCTCGTTCGACTTCGGCA AGGCCATGAGCACCTACCTGCACCAGCACCTGGGGCTGAGCCGCAACTGCCGGCTCATCGAGCTCA AGAGCGCCTGCTACTCCGGGGTCGCCGGGCTGCAGATGGCCGTCAACTTCATCCTGTCCGGCGTGTC GCCGGGGCCAAGGCCCTGGTGGCCTCCGACCTGTCGCGCTTCTCCATCGCCGAAGGGGGAGA GAGCGACACGCCCGGGTGTTCCGCGTCGACGTGGGGGCGAACGGCTACTACGGCTACGAGGTGAT GGATACCTGCCGCCGGTGGCGGACAGCGAAGCGGGAGACGCGGACCTGTCGCTCCTCCTACCT GGACTGCTGTGAGAACGCCTTCCGGGAGTACACCCGCCGCGTCCCCGCGGCGAACTACGCGGAGAG CTTCGGCTACCTCGCCTTCCACACGCCGTTTGGCGGCATGGTGAAGGGCGCCCACCGCACGATGATG CGCAAGTTCTCCGGCAAGAACCGCGGGGACATCGAAGCGGACTTCCAGCGGCGAGTGGCCCCCGGG CTGACCTACTGCCAGCGCGTGGGGAACATCATGGGCGCGACGATGGCGCTCTCGCTCCTCGGGACC ATCGACCACGGCGACTTCGCCACCGCGAAGCGGATTGGCTCTCTCGTATGGCTCGGGGTGCAGCT CGGAGTTCTTCAGCGGCGTGGTGACGGAGGAAGGGCAGCAGCGCAGCGCCCCTGGGGCTGGGA GAAGCGCTGGGGCGCCGGCAGCAGCTCTCCATGCCGGATTACGACGCGCTGCTGAAGGGGAACGGC GGGTGGGCAGGCCCTTGCTCTTGTCGGCGATTCGTGACTTCCATCGCGACTACCAATGGATTT CCTAGCCTCGGGGCTTCGAGCAAAGCCATGTCCAGCGTAGCGACGGCCGTCCCCCTGACGGCCCGTG ACAGCGCGGTGAGCCGCCGGCTGCGAATCACCCCCAGCATGTGCGGCCAGACGTCCTTGTTCGCCGG GCAGATTGGCGACTGGGCATGGGACACCGTCAGCCGCCTGTGTGGCACGGACGTGCTGACCGCGAC CAACGCCTCAGGCGCCCACCTACCTGGCCTTCTATTACTTCCGCATCCGGGGCACGCCCGCGCTG CATCCCGCGCGCTCCGCTCGCCGACACGCTGGACGTCGAAGGCGTACAACTTCGGCAGC GAATCCGTCTGACGGTGCACCGCATCTGCAAGACGGCGGAGGGCGGCGCTCCGGAGGCGGATGCC TTCGGCCATGAAGAGCTGTACGAGCAGCCCAGCCAGCCGCATCTACGCGGAGACCTTCAACCGG TGGATCACGCGCTCGGACGGCAAGTCGAACGAGGCCTGATCAAGTCCTCGCCCGTGGGGTTCCAG TACGCACACCTGCCGCTCTTGCCGGACGAATACTCGCCGCGGGGCCTATGGGGACGCGGGGC CGGGGCACCTTCACGATGTGGACTCCGCGGAGTACCGGCTGACCGTGGACCGCTTCCCGCTGCGCT ACGCGGTGGACGTCATCCGGGACGTCAATGGGGTGGGGCTCATCTACTTCGCGTCGTATTTCTCGAT GGTGGACTGGGCATCTGGCAGCTGGCGAGGCACCAGGGACGCAGCGAGCAGGCCTTCCTGTCGCG CGTGGTGCTGGACCAGCAACTGTGCTTCCTCGGCAACGCGGCGCTGGACACCACCTTCGACATCGAC GTGCAGCACTGGGAGCGGTGGGCGGGGGAAGAGCTGTTCAACGTGAAGATGCGCGAGGGCGC GCAGGCCGGGACATCGCCGTGGCGACGGTCAAGGTGCGCTTCGACGCGCTTCGGAAGGAGGCCG CCGTGGGTGAGCCGATGACAGACGAACAAATCCGCGGAGTCGTGCACCAGTCCATCGTGCGCGTCC TGCCCGCGTGCGCTCCAACGAGATTGCGGGCCACTTGAACCTCCGCGAGCTGGGCGCGGACTCCGT GGACCGGGTCGAGATTCTCACGTCCATCCTGGACAGCCTGCGGCTGCAGAAGACGCCACTGGCGAA GTTCGCCGACATCGCAACATCGACGCGCTGGTGGCGTTCCTGGCCGGTGAGGTCGCGGGTGGCTG AGCGGGTTCCCGGCGGAGTCGGCATCGAGGCCATCAACGCCTACGGCGCGCCGCCTCCATTCCGG TGTTGGACTTGTTCCGGGGCCGGCGGCTGGACCCGAAGCGATTCTCCAACCTGATGATGCAGGAGC GCGGCGTCGCGCTGCCGTTCGAGGACCCCGTCACCAACGCGGTCAATGCGGCGCGGCCCATCCTGG ACTTCAGCAAGTCCATCTCCTCGTATGCGCACGAGCACCTGGGGGCTGAGCCGCCACTGCCGGTTCCT GGAGGTGAAGCAGGCGTGTTACGCCGCCACCGGAGCGCTCCAGCTAGCGCTGGGCTACATCGCGTC GGGCGTGTCACCGGGGGCCAAGGCCCTGGTGATTGCCACGGACGTGACGCTGGTGGACGAGAGCGG TCTGTACTCCGAGCCGGCGATGGGCACCGGCGGCGTCCCGTGCTGCTGGGCGACGAGCCGCGCGT GATGAAGATGGACCTGGGAGCGTTCGGCAACTACAGCTACGACGTCTTCGACACCGCGCGCCCTC GCCGGAGATTGATATCGGCGACGTGGACCGGTCGCTCTTCACGTACCTGGACTGCCTCAAGCACAGC TTCGCCGCGTATGGCCGCCGGGTGGACGTGTCGACTTCGACGTTCGACTACCTGGCGATGC ACACGCCGTTCGCCGGACTGGTGAAGGCCGGGCACCGCAAGATGATGCGCGAGCTCACCCCGTGCG ACGTGGACGAAATCGAAGCGGACTTCGGCCGGCGCGTGAAGCCGTCACTGCAGTACCCGAGTCTGG TCGGGAACCTGTGCTCCGGCTCCGTGTACCTGAGCCTGTGCAGCATCATCGACACCATCAAGCCCGA GCGGTCCGCTCGGGTGGGAATGTTCTCCTATGGGTCGGGTTGCTCGTCGGAGTTCTTCAGCGGCGTC <u>ATCGGCCGGAGTCCGTGTCCGCGCTAGCTGGGTTGGACATCGGTGGCCACCTCCGGGGGGCCCGC</u> CAGCTCACGTTCGACCAATATGTCGAATTGCTGAAAGAGAACCTTCGCTGTCTGGTTCCAACGAAGA ACCGGGACGTGGACGTGGACCCTCCCGCTGGTGACGCGGACGGCGAGCCGCCCCGCGCATGC

5 C) 🙀

AGCGGCCGGGCCGTCAGCATCAGGCCAACGGGCAGACGACGGCCCACCTGGGGGCGGAAATCGCCT CGCTGGCCGTGCCCGAAGGCGTCACCCCACAACTGTGGCGCTCGGCCACGTTTTCGGGGCAGGCCGC ACTGGTGACCGTCCACGAGGCCTGGAACGCGGCGCGCCTCCAGGCCGTCCCCGGACACCGGATTGG ATTGGTGGTGGGGGCACCAACGTGCAGCAGCGCGACCTGGTGCTGATGCAAGACGCCTATCGCGA GCGGGTGCCCTTTCTGCGGGCGGCCTACGGGTCGACCTTCATGGACACCGACCTCGTGGGCCTCTGC ACGCAGCAGTTCGCCATCCACGGGATGTCCTTCACGGTGGGAGGCGCATCGGCCAGTGGCCTGCTG GCGGTCATCCAGGCCGCGGAGGCGGTGCTCTCAAGAAGGGTGGACGTTTGCATCGCCGTGGGGGCG TTCGCGCGGGAGCCGGGCCTGCCGGCCCTTCGACCGGGAGAGTGATGGCTTCATCTTTGGAG AGGCGTGCGGCGCGTGGTGGTTGAGTCTGCGGAGCACGCTCGGCGACGCGGGGTGACTCCTCGCG GCATCCTGTCGGGCTGGGCCATGCAGTTGGACGCGAGCCGGGCCCGTTGTCGTCCATCGAAGGGG AGTCGCAGGTGATTGGGGCTGCGCTGCGGCACGCGGACCTCGCGCGGAGCGGGTGGACTACGTGA ATCCTCACGGCAGCGGTTCGCGTCAGGGGGGATGCCATCGAGCTGGGGGCCTTGAAGGCGTGCGGCC TGACGCACGCCCGGGTCAACACCACGAAGTCCATCACCGGGCATGGCCTGTCCTCGGCGGGTGCCGT GGGGCTCATCGCCACGCTGGTCCAGTTGGAGCAGGGCCGGCTGCACCCGTCCTTGAACCTGGTGGAC CCGATTGATTCATCGTTCCGCTGGGTGGGGCCACCGCGGAGGCCCAGTCCCTCCAGAACGCGCTGG TGCTCGCCTACGGCTCGGCGCATCAACACCGCTGTCGCCGTGCGCCGGAGCGCCACGGAGAGCT GACACGCCATGCAAGCCGCTTCCCCTCCGCACCGCGACTACCAGACGCTCCGGGTCCGCTTCGAGG CGCAGACCTGTTTTCTCCAGCTCCACCGGCCGGATGCGGACAACACCATCAGCCGCACGCTGATTGA CGAGTGCCAGCAGGTGCTCACGTTATGTGAGGAGCACGCCACCACGGTGGTGCTCGAAGGCCTGCC ACACGTGTTCTGCATGGGCGCGGATTTTCGAGCCATCCACGACCGGGTCGACGACGGCCGCCGGGA GCAAGGCAACGCGGAGCAGCTGTACCGGCTGTGGCTGCAACTGGCGACAGGCCCCTACGTGACGGT CGCCCATGTGCAGGGCAAGGCCAACGCGGGCGGCCTGGGCTTCGTCGCCGCGTGCGACATCGTGCT GGCAAAGGCGGAGGTCCAGTTCAGTCTCCCGAGCTGCTGTTCGGGCTGTTCCCCGCCTGCGTGATG CCGTTCCTCGCCCGGCGAATCGGCATCCAGCGGGCGCACTACCTGACGCTGATGACGCGGCCCATCG ACGCGCCCAGGCGCTGAGCTGGGGGTTGGCGGACGCGGTGGACGCCGATAGCGAGAAGCTGTTGC GGCTCCACTTGCGCAGGCTGCGGTGCCTGTCGAAGCCAGCGGTGACCCAGTACAAGAAGTACGCCT CCGAGCTGGGCGGCCAGCTGCTCGCGGCCATGCCCCGGGCCATCTCCGCCAATGAGGCGATGTTCTC CGACCGCGCCACGCTGGAAGCCATCCATCGCTACGTGGAGACAGGCCGACTCCCATGGGAATCATG CACCCTGGTGGATCGCGAGAACAAGAACATGTTCAGCGAGCAGCTCGTGCGCGAGCTCATCACCGT GTTCGGCAAGGTGAATGGAAACGAGCGCTACCGCGCGGTGGTGCTCACCGGCTACGACACCTACTT CGCGCTCGGCGGACCAAGGCCGGCCTGCTGTCCATCTGCGACGGCATCGGCTCCTTCAACGTCACC AACTTCTACAGCCTCGCGCTGGAGTGCGACATCCCGGTGATTTCCGCCATGCAGGGACATGGCGTAG GCGGCGGGTTCGCGATGGGGCTGTTCGCGGACTTCGTGGTCCTGAGCCGGGAGAGCGTCTACACGA CGAACTTCATGCGCTACGGCTTCACGCCGGGGATGGGCGCCACGTACATCGTGCCGAAGCGGCTGG GGTACTCGCTCGGGCATGAGCTCCTGCTCAACGCCAGGAACTACCGCGGCGCCGACCTGGAGAAGC GGGGCGTGCCTTTTCCGGTGTTGCCGCGCAAGGAAGTCTTGCCCCACGCCTACGAGATTGCGAGGGA CCTGGCCGCGAAACCTCGGCTGTCGCTCGTGACGCTCAAGCGGCACCTGGTTCGCGACATCCGCCGA GAGCTTCCGGACGTCATCGAGCGTGAGCTGGAGATGCACGGCATCACCTTCCATCACGACGACGTG AGGAGGCGCATCGAGCAGCTGTTCCTCTGAGGCGCGCCCCTATGTTGAACCTGATCAACAACCACGC ACACGGTTATGTGGTCACGCCCGTGGTCCTGGCCTGCAACGACGCTGGCCTGTTCGAACTCCTGCGG CAGGGACCGAAGGACTTCGACCGGTTGGCGGAGGCATTGCGTGCCAACCGGGGACATCTGCGCGTC GCGATGAGGATGTTCGAATCGCTCGGCTGGGTTCGCCGCGACGCGGATGACGTGTACGCGGTGACG GCGGCGGCGCGCGCATCGGTCCTTCCCCCGCGAGGCGCAGTCGCTCTTCGCGCTGCCCATGGACC GGTACCTGCGCGGGAGGACGGCCTGTCCCTGGCGCCGTGGTTCGAGCGCTCTCGGGCGTCGTGGG ATACCGATGACACGCTGGTGCGCGAGCTGCTCGACGGCGCCATCATCACGCCGCTGATGCTCGCGCT GGAGCAGCGTGGGGGCCTCAAGGAGGCGAGGCGTCTGTCCGACCTGTGGTCCGGGGGGGATGGAA GGGACACGTGCGTCCCGAGGCCGTCCAACACGAGCTGGCCGGGTTCTTCTCCGCGCAGAAGTGGA CGCGTGAGGACGCCGTCGACGCGGAGCTCACGCCCAAGGGCGCCTTCATCTTCGAGCGGGCATTGC TCTTCGCCATCGTCGGCTGTACCGGCCGATGCTGGCCAGCATGCCGCAGCTGCTCTTCGGTGACTG CGACCAGGTCTTCGGGCGGGACGAAGCGGGCCACGAACTGCACCTGGACCGAACCCTCAACGTGAT TGGGAGCGGCCACCAGCACCGGAAGTACTTCGCGGAGCTGGAGAAGCTCATCATCACCGTCTTCGA TGCCGAGAACCTGTCGGCACAGCCGCGCTACATCGCGGACATGGGGTGCGGTGACGGCACGCTCCT GAAGCGGGTGTATGAAACGGTGCTTCGGCACACGCGGCGGGGAAGGGCGCTCGACCGGTTTCCGCT CACGCTCATCGCCGCGGACTTCAACGAGAAGGCCCTCGAAGCCGCTGGGCGGACGCTGGCCGGGTT ggagcacettgccttgcgcgcgcacgtggcgcgcgcgdaccgtctcatcgaggacctgcggcgcg CGGGCTAGCCGAGCCTGAGAATACGCTGCACATCCGCTCGTTTCTCGACCACGACCGTCCCTACCAG CCTCCGGGGACAGGGGGGGCTCCACGCCGGATTCCGTTCGATTCGGTGTTCGTGGGCAAGGCG GGCCAGGAGGTGGTTCCGGCGGAGGTGTTCCACAGCCTGGTGGAGCACCTCGAG

⊈. ₹)

CLAIMS

What is claimed is:


- 1. A purified, isolated and cloned DNA sequence partially encoding a functional portion of a polypeptide component required for the synthesis of antibiotic TA.
- 2. The DNA sequence according to claim 1, wherein said sequence is isolated from *Myxococcus xanthus*.
- 3. A purified, isolated and cloned DNA sequence consisting of a DNA sequence encoding a polypeptide component required for postmodification of antibiotic TA.
- 4. The DNA sequence according to claim 3, wherein said sequence is isolated from *Myxococcus xanthus*.
- 5. A purified, isolated and cloned DNA sequence consisting of a DNA sequence encoding a gene product involved in the regulation of the biosynthesis of antibiotic TA.
- 6. The DNA sequence according to claim 5, wherein said sequence is isolated from *Myxococcus xanthus*.
- 7. A purified, isolated and cloned DNA sequence consisting of a DNA sequence (Seq. ID No:1 and 2) encoding a polypeptide component required for encoding the TA gene cluster.

- 8. The DNA sequence of Seq. ID No:1 and 2 altered by point mutations, deletions or insertions such as the resulting amino acid sequence is truncated.
 - 9. A transformed *E coli* carrying Seq. ID No:1 and 2.
 - 10. A vector which comprises the DNA according to claim 7.
- 11. A host cell, wherein the host cell is selected from the group of suitable eucaryotic and procaryotic cells, which is transformed with the vector according to claim 10.
 - 12. The host cell according to claim 11 which is E. coli.
- 13. A recombinant expression vector comprising a DNA sequence according to claim 7.
 - 14. A cosmid containing the DNA sequence according to claim 7.
 - 15. A method of using the TA genes for combinatorial genetics.
- 16. A-method of-using the TA genes encoding for the synthesis, modification or regulation of antibiotic TA.

TITLE

ABSTRACT OF THE DISCLOSURE

There is provided a purified, isolated and cloned DNA sequence partially encoding a functional portion of a polypeptide component required for the synthesis of antibiotic TA. Also provided are purified, isolated and cloned DNA sequences encoding a polypeptide component required for postmodification of antibiotic TA and encoding a gene product involved in the regulation of the biosynthesis of antibiotic TA. A purified, isolated and cloned DNA sequence having a DNA sequence (Seq. ID No:1 and 2) encoding a polypeptide component required for encoding the TA gene cluster and any mutations thereof is provided. Also provided are methods of using the TA genes for combinatorial genetics and of using the TA genes encoding for synthesis and modification or regulation of antibiotic TA.



Docket	No.
2290.00	076

Declaration and Power of Attorney For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled GENE CLUSTER the specification of which Check one) I is attached hereto. I was filed on January 29, 1999 I Application Number
(check one) is attached hereto. was filed on January 29, 1999 as United States Application No. or PCT International Application Number 09/240,537 and was amended on (if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
(check one) is attached hereto. was filed on January 29, 1999 as United States Application No. or PCT International Application Number 09/240,537 and was amended on (if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
is attached hereto. was filed on January 29, 1999 as United States Application No. or PCT International Application Number 09/240, 537 and was amended on (if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of the section
was filed on January 29, 1999 as United States Application No. or PCT International Application Number 09/240, 537 and was amended on (if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of the section 1.56 in the section
Application Number
Application Number
(if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all informatio known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
(if applicable) I hereby state that I have reviewed and understand the contents of the above identified specification including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the United States Patent and Trademark Office all informatio known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
I acknowledge the duty to disclose to the United States Patent and Trademark Office all informatio known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
known to me to be material to patentability as defined in Title 37, Code of Federal Regulations Section 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of
Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the Unite States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.
Prior Foreign Application(s) Priority Not Claimed
(A) wheel (Country) (Country)
(Number) (Country) (Day/Month/Year Filed)

` ,	(,	()	,
Number)	(Country)	(Day/Month/Year F	iled)
-SB-01 (9-95) (Modified)		P02/REV02	

I hereby claim the benefit unde application(s) listed below:	r 35 U.S.C. Section 119(e)	of any United States provisional
(Application Serial No.)	(Filing Date)	
(Application Serial No.)	(Filing Date)	
(Application Serial No.)	(Filing Date)	
Section 365(c) of any PCT Internations insofar as the subject matter of elunited States or PCT International U.S.C. Section 112, I acknowledge Office all information known to make the subject of the su	tional application designating ach of the claims of this app al application in the manner pa the the duty to disclose to the U the to be material to patentabi the between the filing date of the	any United States application(s), or the United States, listed below and, lication is not disclosed in the prior rovided by the first paragraph of 35 United States Patent and Trademark lity as defined in Title 37, C. F. R., the prior application and the national
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.) (Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
I hereby declare that all statem	ents made herein of my ow	n knowledge are true and that all

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)

Kenneth I. Kohn (30,955)

Send Correspondence to:	Kenneth I. Kohn Kohn & Associates	
	30500 Northwestern Highway, Ste. 410	
- PORTER	Farmington Hills, MI 48334	
Direct Telephone Calls to:	(name and telephone number)	
Kenneth I. Kohn (248) 539-56		
Full name of sole or first inventor		
Eugene Rosenberg		Date
Sole or first inventor's signature	ugane Rosenberg Ergen Rosenberg	Feb. 1999
Residence	7	
Givat Shmuel, Israel		
Citizenship Isreali		
Post Office Address		
18 Rahavat Ilan		
Givat Shmuel		
Full name of second inventor, if ar	ту	
Eliora Ron		Date
Second inventor's signature	ma Kon	Feb. 1999
Residence		
Tel Aviv, Israel		
Citizenship Israeli		
Post Office Address 36 Yehuda Hanasi Street		
Tel Aviv, Israel		

hird inventor's signature	Date Fob 1999
Third inventor's signature	Feb. 1999
Residence	
United Kingdom	
Citizenship	
Israeli	
Post Office Address 23 Crearbill Pond	<i></i>
23 Greenhill Road	<i>F</i>
Leicester, LE2 3DN, United Kingdom	
Full name of fourth inventor, if any	
Yossi Paitan	
Fourth inventor's signature	Date
POULTI IIVEARUI S SIGNATURE	Feb. 1999
Residence	
Rishon Le-Zion, Israel	
Citizenship Israeli	
Israeh	
Post Office Address	
41 Hertzel st	
Rishon Le-Zion, 75296, Israel	
Full name of fifth inventor, if any	
Sifth inventor's signature	Date
Fifth inventor's signature	
Residence	
Residence	
Citizenship	
•	
Post Office Address	
Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
2.106.11	
Post Office Address	